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Summary 
 
CYR61 (Cysteine-rich angiogenic inducer 61) is a matricellular protein that 
regulates cell proliferation, adhesion, migration and cell survival through 
interaction with various types of integrin cell adhesion receptors. At tissue 
level it is implicated in the regulation of embryonic development, wound 
healing and angiogenesis. CYR61 has also been involved in cancer 
progression, however its role appears to be diverse and complex depending 
on the cancer type and stage. Its contribution to metastasis formation is still 
unclear. Previous findings reported by our laboratory demonstrated that 
CYR61 cooperates with αvβ5 integrin to promote invasion and metastasis of 
cancers growing in a pre-irradiated microenvironment. 
In this work, we used an orthotopic model of breast cancer to show for the first 
time that silencing of CYR61 in breast cancer cells suppresses lung 
metastasis formation. Silencing of MDA-MB-231 reduced both local growth 
and lung metastasis formation of tumor cells implanted in a pre-irradiated 
mammary fat pad. CYR61 silencing in tumors growing in non-irradiated 
mammary fat pads did not impact primary tumor growth but decreased lung 
metastasis formation. The effect of CYR61 on spontaneous lung metastasis 
formation during natural cancer progression was further examined by using an 
experimental model of metastasis. Results from these experiments indicate 
that CYR61 is critically involved in promoting cancer cells entry into lung 
parenchyma rather than later steps of colonization. In vitro experiments 
showed that CYR61 promotes tumor cell spreading, migration and 
transendothelial migration. CYR61 also supported colony formation under 
anchorage-independent condition and promotes resistance to anoikis through 
the involvement of β1 and β3 integrin. These results indicate that CYR61 
promotes lung metastasis of breast cancer by facilitating extravasation into 
lung parenchyma through enhanced motility, transendothelial migration and 
resistance to anoikis. 
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Résumé 
 
CYR61 (Cysteine-rich angiogenic inducer 61) est une protéine matricellulaire 
qui régule la prolifération, l'adhérence, la migration et la survie des cellules 
par son interaction avec différents types de récepteurs d'adhésion cellulaire 
de la famille des intégrine. Au niveau des tissus, CYR61 est impliquée dans la 
régulation du développement embryonnaire, de la cicatrisation et de 
l'angiogenèse. CYR61 a également été impliquée dans le cancer, mais son 
rôle semble être divers et complexe en fonction du type du cancer et de son 
stade. Son rôle dans la formation des métastases n'est pas encore clair. Des 
résultats antérieurs rapportés par notre laboratoire ont montré que CYR61 
coopère avec l'intégrine avß5 pour favoriser l'invasion et la métastase de 
tumeurs se développant dans un micro-environnement pré-irradié. 
Dans ce travail, nous avons utilisé un modèle orthotopique de cancer du sein 
pour démontrer pour la première fois que l’extinction (silencing) du gène 
CYR61 dans le cancer du sein réduit la formation de métastases pulmonaires. 
L’extinction de CYR61 dans la lignée cellulaire de cancer du sein humain 
MDA-MB- 231 réduit à la fois la croissance local ainsi que la formation de 
métastases pulmonaires à partir de cellules implantés dans les coussinets 
adipeux mammaires pré-irradié. L’extinction de CYR61 dans des tumeurs 
grandissant dans les coussinets adipeux mammaires non irradiées n’a pas 
d'incidence sur la croissance tumorale primaire mais réduit la formation des 
métastases pulmonaires. Par la suite nous avons examiné l'effet de CYR61 
sur la formation de métastases pulmonaires en utilisant un modèle 
expérimental de métastase. Les résultats de ces expériences indiquent que 
CYR61 est impliquée de manière cruciale dans les étapes précoces de la 
formation de métastases, plutôt que dans les étapes tardives de colonisation 
du poumon. Des expériences in vitro ont montré que CYR61 favorise 
l’étalement, la migration et la transmigration endothéliale des cellules 
tumorales. CYR61 favorise également la formation de colonies dans des 
conditions indépendante de l'ancrage et la résistance à l’anoïkis par 
l’engagement des intégrines β1 et β3. Ces résultats indiquent que CYR61 
favorise les métastases pulmonaires du cancer du sein en facilitant 
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l'extravasation dans le parenchyme pulmonaire grâce à la stimulation de la 
motilité, de la migration transmigration endothéliale et de la résistance à 
l'anoïkis.  
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Introduction 
 
1. Cancer as a major cause of deaths 
 
Cancer is one of the major causes of death throughout the world. From the 
reports of the World Health Organization (WHO) and of the International 
Agency for Research on Cancer in 2008, cancer claimed 14% of adult lives 
aged between 30 to 70, which corresponds to about 20% of all deaths 1. The 
latest GLOBOCAN 2012 report further reported an increasing incidence of 
cancer and deaths caused by cancer, with the numbers of 12.7 million and 7.6 
million, respectively in 2008, rising to 14.1 million and 8.2 million in 2012 2. 
 
According to this report, the percentage of death caused by cardiovascular 
diseases, diabetes, and chronic respiratory conditions dramatically decreased 
with the economical development, while death caused by cancer showed no 
significant reduction in high-income area. This observation calls for an urgent 
need to improve our current knowledge of cancer initiation and progression as 
well as develop novel clinical therapies.  
 
2. Cancer development and progression 
 
Cancer arises from normal tissues through a complex, multistage process. In 
2000, six hallmark capabilities of cancer cells were proposed by Hanahan and 
Weinberg in order to describe comprehensively how normal cells become 
transformed and progressively acquire a cancerous phenotype. These 
hallmarks include self-dependence on growth signaling, insensitivity to anti-
growth signals, unlimited replication potential, escape from cell death, 
induction of angiogenesis, and activation of mechanisms of local invasion and 
distant metastasis formation 3. These traits depict how cancer cells generate a 
locally growing tumor and develop the ability to migrate to secondary organs. 
Moreover, results from further investigations during the following decade have 
suggested two additional capabilities of cancer cells: reprogramming cellular 
metabolism and escaping from immune surveillance 4. 
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Reprogrammed cellular metabolism provides cancer cells with an alternative 
way to acquire energy and macromolecules required for rapid proliferation 5. 
At the same time, cancer cells also develop diverse escape mechanisms to 
avoid attack and clearance from immune system 6,7. 
 
Underlying these hallmarks are two enabling characteristics. First, heritable 
changes in DNA sequence (i.e. mutations,) epigenetic modifications and 
genomic instability allow cancer cells to cumulate alterations in gene 
expression, which in turn favor their own expansion. This is achieved by 
activating oncogenes, inactivating tumor suppressor genes, abrogating 
genome maintenance / DNA repair systems and accelerating the generation 
of further mutations 8,9. 
 
The second characteristic is tumor-promoting inflammation. Besides the ability 
to escape from detection and clearance by the immune system, cancer cells 
can in turn utilize the immune system to their advantage by recruiting specific 
immune cells to the tumor tissues, mostly innate immune cells, and educate 
them to their needs. These tumor-promoting immune cells provide cancer 
cells with communication molecules (i.e. cytokines, growth factors, 
chemokines), matrix proteins and matrix degrading enzymes that facilitate 
cancer cell growth, survival, invasion and dissemination 10-12. 
 
3. Tumor microenvironment 
 
Besides the tumor-promoting immune inflammatory cells, there are also other 
types of stromal cells, which have been shown to promote cancer 
progression. They include cancer-associated fibroblasts, endothelial cells, 
pericytes, and progenitor cells as the origin of stroma cells 13,14. Cancer cells 
and stromal cells interact reciprocally by direct physical interaction or though 
the release of soluble factors, matrix proteins and matrix-degrading enzymes, 
further modifying the whole microenvironment and promoting tumor 
progression. 
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Cumulating data indicate that cancer cells actively recruit cells from 
neighboring tissue or distant sites, in particular from the bone marrow, to 
constitute a microenvironment that favors cancer development. In turn, tumor 
microenvironment-derived stimuli affect cancer cells by modulating their gene 
expression and behavior.  
 
4. Metastasis 
 
Cancer cells can leave the primary tumors to form secondary tumors at 
distant sites, so called metastases. Compared with the bulk of cells in the 
primary tumor, metastatic cells have a stronger ability to migrate to and adapt 
to conditions present in the novel tissue environment. Metastatic cancer cells 
are also more resistant to traditional chemotherapy drugs, which makes it 
more difficult to target them 15. Eventually, metastasis is the primary cause of 
death for about 90% of cancer patients 16. In spite of its clinical relevance, our 
knowledge of metastasis formation is still incomplete. The conceptual 
understanding of molecular mechanisms of metastasis, as a basis for the 
development of novel therapeutic strategies, still needs to be improved. 
Metastasis, like the process of cancer progression, also develops as a 
multistep process (Fig.1) 17. 
 
4.1. Local invasion 
 
The ability to migrate and invade into surrounding tissue is a critical 
characteristic of the transition from a benign tumor to a malignant cancer. In 
general, tumor cells have to first disassemble junctional complexes between 
neighboring cells, digest underlying matrix substrates and connective tissues 
at the outer layer of the tumor mass, acquire the ability to rearrange the 
cytoskeleton and migrate following chemotactic gradients or mechanical flow. 
Several mechanisms have been discovered for cancer cells to undergo local 
invasion. Considering that 90% of cancers are derived from poorly motile 
epithelial tissues, the most prevailing model is the so-called “epithelial to 
mesenchymal transition” (EMT). This model describes the genetic, 
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morphological and functional alterations which turn tightly-bound epithelial 
cells into motile and more aggressive mesenchymal-like cells 18. 
 
 
 
Figure 1.  Schematic illustration of metastasis cascade. From 17 
The development of metastasis could be dissected into multiple steps. With expanding 
primary tumor masses (a), tumor cells initiate angiogenesis (b) to enrich their supply of 
oxygen and nutrients. Some tumor cells acquire higher mobility, digest the surrounding matrix 
to start local invasion (c), and then enter into circulation through blood/lymphatic vessels (d). 
Disseminated tumor cells inside circulation interact with platelets and lymphocytes, and have 
to escape from immune surveillance and detachment-induced cell death (anoikos) (d). Tumor 
cells arrive at the secondary organs then penetrate the vessel wall (extravasation) (e), and 
adapt to the local microenvironment to eventually develop metastasis (colonization) (f). 
 
 
 
4.1.1. EMT in cancer progression 
 
EMT is defined as a transition process by which epithelial cells lose 
intercellular junctions, diminish apical-lateral polarity, repress expression of 
epithelial markers (i.e. E-cadherin, ZO-1), upregulate mesenchymal markers 
(i.e. N-cadherin, vimentin, fibronectin), reorganize cytoskeleton and acquire 
© 2002 Nature Publishing Group
P E R S P E C T I V E S
independent characteristics. Moreover,
because tumour progression can occur over
periods of years, the behaviour of a neoplasm
can vary at different disease stages.
This evolution has been attributed to
acquired genetic variations in the cells that
populate a neoplasm21. Peter Nowell pre-
dicted that those tumour cells that progress
to an advanced stage ofmalignancy — that
is,metastatic cells — would be less stable,
genetically, than non-metastatic tumour
cells. This hypothesis was tested using the
Luria and Delbruck fluctuation analysis22.
This analysis is based on acquisition of
mutations that confer resistance to the
metabolite 6-thiopurine (caused by a muta-
tion in hypoxanthine/guanine phosphori-
bosyl-transferase) and resistance to the
drug ouabain (caused by a mutation in the
advent of radioactive labelling of tumour
cells. A thorough review of the literature on
this topic, however, could have been accom-
plished in one night12,13. Bernard and Edwin
Fisher reported that they could quantify
metastasis by tracking tumour cells that
were labelled with 51chromium. The results,
however, were controversial, as 51chromium
was released by dead cells and re-internal-
ized by living cells14.
To overcome this deficiency, researchers
began to label cancer cells with 125iodine-
iodo-deoxyuridine, which is incorporated
into the DNA and is therefore not released
from cells. These studies showed that within
24 hours after entry into the circulation, less
than 0.1% of tumour cells are still viable,
and that less than 0.01% of these cells, when
introduced into the circulation, survive to
produce metastases15. Therefore, only a few
cells in a primary tumour can give rise to a
metastasis16. This prompted the question of
whether the development ofmetastases rep-
resents the fortuitous survival and growth of
very few neoplastic cells, or whether it rep-
resents the selective growth of unique sub-
populations of malignant cells that are
endowed with special properties.
Subsequent studies clearly showed that neo-
plasms are biologically heterogeneous and
that the process ofmetastasis is selective.
Biological heterogeneity in neoplasms
At the time of diagnosis,many human and
animal tumours are heterogeneous and
contain numerous subpopulations of cells
that have different biological characteris-
tics, including metastatic potential17–19. This
biological diversity can result from a
tumour’s multicellular origin, but in
tumours that originate from a single trans-
formed cell, the source of the biological
diversity is less clear.
Clinical and experimental studies have
shown that neoplasms undergo a series of
changes during the course of the disease.
For example, a growth that is initially
benign can change into a malignant, lethal
tumour. Leslie Foulds described this 
phenomenon of tumour evolution as ‘neo-
plastic progression’, and defined it as
“acquisition of permanent, irreversible
qualitative changes in one or more charac-
te istics of a neoplasm”20. This evolution of
tumours is gradual, and tumour cells pro-
ceed towards increased autonomy from
their host by a temporal change in various
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David Tarin and colleagues
reported the evidence of
organ-specific metastasis in
ovarian carcinoma patients
who were treated with
peritoneovenous shunts
Therapy of cancer
metastasis was
directed against host
factors (angiogenesis,
organ growth factors)
The metastatic
heterogeneity and
organ specificity of
human tumours was
confirmed by studies
using immune-
incompetent mice
In situ hybridization analyses,
immunohistochemistry and
laser-capture microdissection
techniques show the genetic,
biological and metastatic
heterogeneity of neoplasms
1984 1990s 2000s
a  Primary tumour b  Proliferation/
     angiogenesis
c  Detachment/
     invasion
d  Embolism/circulation
e  Extravasation Adherence to 
vessel wall
Arrest in organs
Metastasis
Transport
Lung Heart
Interaction with platelets,
lymphocytes and other 
blood components
f
Establishment of a 
microenvironment
Proliferation/
angiogenesis
Lymphatics,
venules,
capillaries
Figure 2 | The main steps in the formation of a metastasis. a | Cellular transformation and tumour
growth. Growth of neoplastic cells must be progressive, with nutrients for the expanding tumour mass
initially supplied by simple diffusion. b | Extensive vascularization must occur if a tumour mass is to
exceed 1–2 mm in diameter39. The synthesis and secreti n of angiogenic factors establish a capillary
network from the surrounding host tissue39. c | Local invasion of the host stroma by some tumour cells
occurs by several parallel mechanisms40. Thin-walle  venules, such as lymphatic channels, offer very little
resistance to penetration by tumour cells and provide the most common route for tumour-cell entry into
the circulation12,41. d | Detachment and embolization of single tumour cells or aggregates occurs next,
most circulating tumour cells being rapidly destroyed. After the tumour cells have survived the circulation,
they become trapped in the capillary beds of distant organs by adhering either to capillary endothelial
cells or to subendothelial basement membrane that might be exposed27. e | Extravasation occurs next —
probably by mechanisms similar to those that operate during invasion. f | Proliferation within the organ
parenchyma completes the metastatic process. To continue growing, the micrometastasis must develop
a vascular network39 and evade destruction by host defences. The cells can then invade blood vessels,
enter the circulation and produce additional metastases6,7.
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spindle-shaped morphology as well as migratory ability. To date, TGFβ has 
been recognized as the most potent molecule in orchestrating EMT 19,20. 
Globally, many signaling pathways can contribute to EMT. They include Wnt-, 
Notch-, Hedgehog-, Ras-, NFκB- dependent pathways. Many growth factors 
frequently utilized by cancer cells to escape from growth control or acquire 
malignant traits, such as invasion and metastasis, are also implicated in the 
regulation of EMT (i.e. EGF, FGF, HGF, IGF, PDGF) 21.  
 
EMT has been originally recognized as an important step during early 
embryogenesis, such as gastrulation and neural crest cell migration. In 
adulthood, EMT may occur during tissue repair, wound healing or fibroblast 
generation from epithelial cells 22. During cancer progression, EMT confers to 
tumor cells the capability of breaking cell-cell adhesion to acquire motility. 
Some EMT-associated genes have been identified to contribute to 
intravasation and extravasation 21. However, it is still controversial whether 
EMT takes place during later stages of metastatic cascade, and whether 
tumor cells could really reach target organs to form metastasis with a 
mesenchymal phenotype. The main argument challenging this notion comes 
from histopathological evidence that metastases often display epithelial 
morphology similar to their primary tumors, and that one of the epithelial 
markers, cytokeratin, is often used for detecting metastatic carcinoma cells 
within distant organs. To solve this apparent contradiction, three models were 
further proposed: (1) incomplete EMT, (2) reversibility of EMT at metastatic 
site (i.e. mesenchymal-epithelial transition, MET), and (3) collective migration 
of cells retaining epithelial morphology 23. These hypotheses highlight the 
importance to understand epithelial plasticity and reversible transition 
between epithelial and mesenchymal phenotypes during metastasis.  
 
4.2. Angiogenesis and intravasation 
 
The concept of tumor angiogenesis is based on the observation that growing 
tumors can induce the formation of neo-vessel to improve the supply of 
oxygen and nutrients, compared to passive diffusion. Blood flow also brings 
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diverse signaling molecules to tumors, which might trigger the cancer cells to 
invade through basement membrane and endothelial layer of vessel wall to 
penetrate into the circulation system. In addition to blood vessel systems, 
recent studies have also recognized the lymphatic vessel system as an 
alternative route for cancer cells to leave the primary tumor and to 
metastasize to distant organ. 
 
4.3. Survival in the circulation 
 
Before reaching the target organs, intravasated and circulating cancer cells 
have to escape from anoikis (i.e. suspension-induced cell death), mechanical 
damages by shear stress, and attack from the immune system. Investigations 
on these circulating tumor cells (CTC) are relatively rare compared to studies 
on the other steps of metastasis, mostly due to the limitation of detection 
techniques for CTCs. However, it has been shown that tumor cells in the 
circulation can associate with platelets and benefit from their protection from 
shear stress damage and immune surveillance 24. Moreover, platelets also 
become activated through interaction with tumor cells and release growth 
factors or signaling molecules to induce growth pathways or to sustain EMT 
programs in cancer cells 25,26. On the other hand, several molecular 
mechanisms used by cancer cells to escape from anoikis have also been 
proposed, including caspase-dependent intrinsic/extrinsic pathways regulated 
by Bcl-2 family proteins 27, and a novel caspase-independent pathway 
mediated by the balance between Bit1 and TLE-1 28,29.  
 
4.4. Extravasation 
 
When reaching the target organ, circulating cancer cells have to adhere to the 
inner endothelial layer and then penetrate the vessel wall to reach the 
underlying parenchyma. Like the process of intravasation, the mechanisms 
adopted by cancer cells to extravasate are not yet well understood. 
 
4.5. Colonization 
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In the secondary organ, there are still several critical hurdles that the 
extravasated cancer cells have to overcome before they could eventually 
develop metastases. First of all, cancer cells are residing in a new 
microenvironment composed of ECM proteins and stroma cells different from 
those at the primary site. It has been proposed that the different 
microenvironment might be responsible for the death of most of the 
disseminated cancer cells in a process that may resemble anoikis. Therefore, 
these cancer cells have to maintain, at least initially, their survival and self-
renewal capacity without the support from the original microenvironment. 
Besides evading the recognition and clearance from immune system, they 
also activate and differentiate immune/inflammatory cells into tumor-
promoting cells. For example, bone marrow derived cells (BMDC) have now 
been proposed to play a supportive role at the metastatic site. The 
characterization of cancer-promoting type 2 macrophages (M2) and 
neutrophils revealed that these immune/inflammatory cells could be further 
educated by metastatic cancer cells to support their survival and stemness 
features upon dissemination. Studies demonstrated that some primary tumors 
can promote the recruitment of BMDC to pre-metastatic sites before the 
arrival of metastatic cancer cells, thereby preparing a better soil for cancer 
cells to seed and form metastasis 30,31. 
 
4.6. From micro-metastasis to macro-metastasis 
 
Not all newly formed micro-metastases are able to form macro-metastases. 
Some micro-metastases become dormant and some eventually disappear. 
These dormant micro-metastases can stay latent from months to decades. 
How dormant cells adapt to the microenvironment and reactivate under such 
quiescent status is not well understood. Although genome instability is a 
hallmark of cancer, reactivation of dormant cells driven by genetic mutation is 
unlikely to occur in the absence of sustained replication 32. Therefore, it is 
proposed that dormant disseminated cancer cells acquire proliferative 
capacities through signals generated from the interaction with the 
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microenvironment. For instance, the matrix proteins tenascin-C and periostin, 
secreted by metastatic cancer cells and stromal fibroblasts, were shown to 
promote outgrowth of micro-metastases through Notch, Wnt and integrin 
pathways eventually leading to the formation of macroscopic lesions 33-35. In 
the end, these macro-metastases will become novel sources of cancer cell 
spreading into the circulation to form tertiary metastases or seed back to the 
primary tumor site 31. 
 
Each step of the metastatic cascade could be potentially rate limiting during 
the process of metastasis formation. In fact, formation of metastasis is 
extremely inefficient. Results from injecting intravenously radiolabeled 
melanoma cells to mice showed that only 0.1% of injected cells were still alive 
24 hours after injection, and less than 0.01% of the injected cells could 
successfully develop lung metastasis 36. Another study of melanoma 
metastasis to liver showed that although 80% of injected cells extravasated 
into the liver by day 3, only 2% of the cells were able to initiate the formation 
of micro-metastases. On day 13, most of the micro-metastases failed to 
maintain cell growth and only 0.018% of injected cells could finally generate 
macro-metastases 31,37. 
 
5. Metastasis organ tropism - Seed and soil theory 
 
The multistep progression of metastasis suggests that cancer metastasis is a 
highly selective process rather than a random event. Based on both clinical 
and experimental observations, it appears that some tumor types tend to 
metastasize to specific organs. This phenomenon has been referred to as 
“metastasis organ tropism”. For example, breast cancer cells tend to 
metastasize to lung, bone, liver and, in a more advanced stage, to brain 38. 
Bone metastasis is frequently diagnosed among prostate cancer patients 39 
and brain metastasis in lung cancer patients 40. In contrast, melanoma 
metastatizes to multiple organs, in particular to skin, lung, brain and liver 41. 
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The concept of organ tropism has been originally proposed by Stephan Paget 
in 1889 and published as the “seed and soil” hypothesis 42. Based on autopsy 
of female breast cancer patients, he found a tendency of metastasis to seed 
to liver, bone, and ovary instead of spleen, which contradicted the theory that 
metastasis simply develops following the mechanical arrest of cancer cells in 
vessels based on the anatomy of the blood supply. In his theory, tumor cells 
behave like “seeds”, which can only form metastasis if they disseminate in the 
appropriate “soil”, standing for selected organs in this metaphor 43. 
 
To date, this theory has been widely accepted and supported by numerous 
experimental data. In particular, Filder and co-workers have shown that 
inoculating B16 melanoma cells into mice generated metastatic lesions in 
pulmonary and ovarian tissues engrafted into muscle, while implanted renal 
tissue showed no metastatic lesion 44. Molecular mechanisms responsible for 
this tropism have also been unraveled. In breast cancer, the interaction 
between cancer-expressed chemokine receptors (CXCR4/CCR7) and distant 
organ-expressed chemokine ligand (CXCL12/CCL21) promotes metastasis 
through facilitating chemotaxis, arrest and invasion to lymph nodes and lung, 
respectively. In the case of melanoma metastasis, interaction between the 
chemokine receptors CCR10 and the chemokine CCL27 seems to play a 
critical role 45. 
 
6. The pre-metastatic niche 
 
With the conceptual advances on tumor microenvironment, the effect of the 
stroma on metastasis formation in secondary lesion has also been 
highlighted. It is proposed that tumors are able to modify tissue components in 
distant organ to create a more metastasis-supportive microenvironment 
before disseminated tumor cells (DTCs) physically arrive at the site of 
metastasis. Kaplan et al. showed that tumor cells could prepare such pre-
metastatic niche in advance by activating the expression of fibronectin at the 
secondary site and directing VEGFR1+/VLA4+ BMDCs toward this location, 
thereby determined which organ would be colonized by metastasis, in this 
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case the lung 46. Moreover, S1PR1-STAT3 signaling is also crucial for tumor-
promoting myeloid cells to mobilize to and to colonize the prospective 
metastatic site. This signaling cascade could further regulate proliferation and 
survival of other metastasis-promoting stroma cells 47. 
 
In addition, ECM remodeling enzymes are also conditioned by tumor or 
“activated” stroma cells. Lysyl oxidase (LOX) released by hypoxic breast 
cancer cells was shown to accumulate at pre-metastatic niche and crosslink 
collagen in order to facilitate the entry for tumor-promoting myeloid cells 48. 
Endothelial cells, MAC1 (CD11b)+ macrophages and VEGFR1+ BMDCs in 
lung facilitate lung metastasis formation through the expression of matrix 
metalloproteinase-9 (MMP-9), which could process the ECM and release 
growth factors and chemokines in the lung microenvironment. 46,49. 
 
7. Linear progression model and parallel progression model 
 
It is generally accepted that the acquisition of metastatic traits and capabilities 
requires additional genetic alterations beyond those responsible for malignant 
cellular transformation 15. Many models have been proposed to describe the 
development of genetic changes during tumor progression toward metastasis 
formation 38. These models can be reduced into 2 fundamental models: the 
linear progression and parallel progression models (Fig. 2) 32. 
 
As a prevailing model, linear progression model describes metastasis as the 
end product of the sequential accumulation of genetic and epigenetic 
alterations during primary tumor development. Therefore, metastasis inherits 
malignant traits from primary tumor and the prognosis and targeting therapies 
are selected based on the analysis of the primary tumor 32. This model also 
predicts that metastasis is a rather late event during natural tumor 
development and the risk of its occurrence correlates with primary tumor size.  
 
However, the detection of disseminated tumor cells (DTCs) in ectopic sites 
during early tumor progression and the advent of whole genome analysis of 
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single tumor cells have suggested a second theory of metastasis - the parallel 
progression model. In this model, tumor cells escape from the primary tumor 
before they acquire full oncogenic capacities and further gather malignant 
hallmarks upon dissemination independently of primary tumor evolution 32,50. 
Analysis of paired DTCs and primary tumor from breast, prostate and 
esophagus cancer patients showed that DTCs have less or different genetic 
aberrations than primary tumor cells 51-53. This discordance also exists among 
DTCs isolated from different sites. Divergence of oncogenic mutation sites 
between primary tumors and metastases, including KRAS and EGFR, further 
support this model of parallel progression 32. According to this notion, 
therapeutic strategies should be reconsidered. Besides the targeting therapy 
selected based on primary tumor subtype, alternative combined therapies 
may be adopted depending on the genetic alterations of DTCs, since these 
early disseminated tumor cells may already develop different survival 
strategies within the secondary microenvironment compared to primary 
tumors 32. Such approach would require a systematic analysis of DTCs 
(Fig.2). 
 
Nature Reviews | Cancer
Primary tumour
Primary tumour
DTC
DTC at 
different sites
First metastasis Second metastasis
Analyse tumour
and select therapy
Analyse metastasis
and select therapy
a
b Identification of initiating or early 
changes for therapy target selection
Cell cluster Small colonies Early metastasis
Identification of tumour 
subtype; primary tumour
less relevant for detailed 
response prediction
Select therapy
against DTC
Select therapy
against cell 
cluster
Select therapy
against small 
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Site-specific evolution
of genes53; clearly, paired samples are likely to 
be similar compared with samples from unre-
lated individuals. Furthermore, if primary 
tumours and metastases influence or create 
environments (niches) independently of ana-
tomical location, concordant gene expression 
profiles are broadly expected. Therefore, gene 
expression profiling may not be optimal for 
characterizing clonal relationships between 
primary tumours and metastases.
The linear progression model. The genetics 
of tumour cells detected in lymph nodes 
or bone marrow at the time of surgery 
contradict the linear progression model. 
Unexpectedly, putatively fully malignant  
(genetically advanced) tumour cells dis-
playing the genetic alterations of primary 
tumours rarely disseminate to bone marrow 
or lymph nodes36,37,39. However, this could 
be an artefact of the detection assays, which 
relied on the expression of cytokeratin 8, 
cytokeratin 18, cytokeratin 19 or EPCAM, 
which are strongly expressed by primary 
tumour cells. The findings do not exclude 
the possibility that DTC populations exist in 
which the epithelial markers cytokeratin 8, 
cytokeratin 18, cytokeratin 19 and EPCAM 
are not expressed and therefore are not 
detected. Such marker-negative cells are pos-
tulated to display genomic aberrations that 
are distinct from those of marker-positive 
DTCs, but harbour the same genomic altera-
tions of primary tumour cells. The absence 
of such marker-negative DTCs would be 
incompatible with linear progression.
The high frequency of distinct genetic 
alterations in primary tumours and mani-
fest metastasis is also difficult to reconcile 
with linear progression. At best, disparities 
between matched pairs may indicate unde-
tected clones within the primary tumour that 
metastasize, but even this would mean that a 
major correction of the model was required.
The parallel progression model. The data 
outlined above indicate that dissemination 
is not commonly a late event in the progres-
sion of breast, prostate and oesophageal 
cancers. This begs the question: when does 
dissemination commence? In mouse mam-
mary tumour virus (MMTV)–Erbb2 and 
MMTV–PyMT (polyoma middle T antigen) 
transgenic mouse models with spontane-
ously arising mammary cancers, DTCs were 
demonstrated in bone marrow and lung 
tissue before the primary tumour became 
morphologically invasive54. Transmission 
electron microscopy revealed that individual 
cells break through the basement membrane 
during pre-invasive atypical hyperplasia. 
Subsequent detection of cytokeratin-positive 
cells in the bone marrow of patients with 
ductal carcinoma in situ, a non-invasive 
lesion, established the rel vance of the 
mouse model for human cancer54 and indi-
cates that tumour cells disseminate early in 
the morphological development of breast 
cancer (although ductal carcinoma in situ 
patients do, rarely, develop metastasis after 
surgery).
Although disparities between primary 
tumours and manifest metastasis are an 
expected consequence of the early dis-
semination of still evolving tumour cells and 
site-specific selection pressures, how can 
the similarities between primary tumours 
and metastases be explained? Divergence 
depends not only on factors outlined above, 
but also on whi h mutations DTCs carry 
from the primary site and the degree to 
which these changes restrict the mutational 
ranges of metastatic founder cells. However, 
the range of mutations in human cancers that 
lead to ‘fitter’ cells is apparently limited, and 
selection therefore results in the independent 
acquisition of identical solutions. For exam-
ple, BRAF mutations occur at codon 600, 
KRAS at codons 12, 13 or 61 (see Catalogue 
of somatic mutations in cancer in Further 
information) and 80% of PI3K mutations 
are also found in three hotspots55. Likewise, 
chromosomal abnormalities do not seem to 
be random. Analysis of about 6,000 CGH 
profiles from 22 cancer types revealed a 
Figure 4 | Consequences of the two models for therapy research and clinical decisions. a | The 
late dissemination and metastatic cascade model predicts that disseminating tumour cells (DTCs) 
resemble the most aggressive clone and therefore the tumour at time of diagnosis. Primary tumours 
are therefore good surrogate markers to select therapies. As the cells adapt by epigenetic modes, no 
further progression is needed and genetic targets (mutations and gene amplification leading to onco-
gene addiction) are identical to those in the primary tumour. Catch-all therapies can be selected on 
the basis of analysis of the primary tumour. b | Parallel progression complicates therapy selection. 
Although tumour cells at primary and distant sites might converge on similar genomes (chromosomal 
aberrations and point mutations) this cannot be confirmed without direct analysis of systemic disease. 
Moreover, genomes may vary between different sites and undergo independent progression. Several 
questions remain to be assessed: whether specific genetic changes are selected at different sites; 
whether different targeting strategies need to be applied for DTCs, small clusters and small colonies; 
and whether early genetic changes shared among all cells are key to eradicating systemic cancer.
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Figure 2.  Clinical therapeutic strategies depending on different 
progression models. From 32. 
(A) In linear progression model, it is hypothesized that disseminated tumor cells (DTCs) and 
metastatic cell colonies are generated from the most aggressive clones among the primary 
tumors and disseminate during late stages of cancer progression. Additional genetic 
mutations are not necessary to develop metastasis. Therefore, the analysis of primary tumor 
is sufficient for choosing therapies targeting metastases. 
(B) From the parallel progression theory, DTCs are considered to leave the primary tumor 
and form metastasis during early stages of tumor development. In this case these tumor cells 
could gather distinct mutations in parallel of primary tumor progression. On the basis of 
independent progression, additional analysis on both DTCs and metastatic colonies may be 
necessary in order to select the most appropriate therapies for treating metastases. 
 
 
 
Regardless of the progression models, high genomic instability and mutations 
occurrence allow cancer cells to keep their diversity among the whole 
population as well as the plural and dynamic interactions within the 
microenvironment. Therefore, more investigations still need to be conducted 
to unravel the mode of progression of cancer metastasis as well as the role of 
the microenvironment. 
 
 
8. CYR61 (Cysteine-rich angiogenic inducer 61) 
 
8.1. Structure of CYR61 
 
CYR61 (Cysteine-rich angiogenic inducer 61) was first identified as an 
immediate-early gene induced by growth factor stimulation 54. CYR61 belongs 
to the CCN (CYR61, CTGF and NOV) family of matricellular proteins and 
shares structural homology with other family members. There are six 
members in the CCN family: CYR61 (CCN1), connective tissue growth factor 
(CTGF, CCN2), nephroblastoma overexpressed protein (NOV; CCN3), and 
Wnt-inducible and secreted protein-1-3 (WISP-1-3; CCN4-6) 55,56. 
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CYR61 consists of 381 amino acids with an N-terminal signal peptide for 
secretion 54. Following the signal peptide are four conserved domains 
homologous to insulin-like growth factor-binding protein (IGFBP), von 
Willebrand factor type C repeats (VWC), thrompospondin type 1 repeat (TSP), 
and a carboxyl-terminal (CT) domain containing a cysteine knot motif 55. 
Among the four domains, VWC, TSP and CT homology domains have been 
described to contain integrin binding sites (Fig. 3) 57.  
 
 
 
 
 
Figure 3.  Schematic structure of CCN proteins. From 57. 
SP: N-terminal secretory signal peptide; IGFBP: insulin-like growth factor-binding protein; 
VWC: von Willebrand factor type C repeat; TSP: thrompospondin type 1 repeat; CT: carboxyl 
terminal domain containing a cysteine-knot motif (absent in CCN5); HSPG: heparin sulfate 
proteoglycan. Black and hatched bars indicate integrin or HSPG binding sites. Binding 
integrins are indicated below.  
 
 
 
8.2. Regulation of CYR61 expression 
 
As an immediate-early gene, the expression of CYR61 RNA is activated 
within minutes of serum stimulation and lasts until several hours 58. 
Transcription of these immediate-early genes does not require de novo 
protein synthesis, and could therefore respond to external stimulation within a 
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short time 54. Expression of CYR61 is regulated by a broad range of stimuli, 
including: growth factors (i.e. PDGF, FGF) 54, inflammatory cytokines (i.e. IL-
1β, TNFα) 59, phospholipids (i.e. S1P, LPA) 60,61, TGFβ 62, phorbol ester 12-O-
tetradecanoyphorbol-13-acetate 54, thrombin 63, estrogen 64, prostaglandin E2 
59, vitamin D3 65, angiotensin II 66 and even UV light and mechanical forces 
67,68, implying diversified roles of CYR61 among cell-environment interactions 
69. 
 
8.3. Cellular functions of CYR61 
 
Several integrins have been reported to interact with CYR61, such as α2β1, 
α6β1, αvβ1, αvβ3, αvβ5. In addition, CYR61 also binds to cell surface heparin 
sulfate proteoglycans (HSPG) 70. It is generally considered that CYR61 
modulates cellular functions by binding to different integrins in different cell 
types. For example, CYR61 enhances endothelial cell adhesion through 
interaction with αvβ3 integrin 71, and also mediates adhesion of fibroblasts and 
smooth muscle cells through α6β1 and HSPG 72,73, platelets through α2bβ3 74, 
monocytes and macrophages through αMβ2 75,76. In addition, by interacting 
with different integrins, CYR61 was shown to elicit distinct cellular responses 
in the same cell type. In fibroblasts, CYR61 regulates cell adhesion, 
senescence and apoptosis through α6β1 and HSPG 72,77-79, migration through 
αvβ5 80, proliferation through αvβ3 80 ; while in activated endothelial cells, αvβ3 
integrin mediates most of the CYR61 cellular functions including cell 
adhesion, migration, survival and tube formation 71,81,82. All these 
investigations strongly suggest that the cellular functions of CYR61 depend on 
the expression profile of cell surface receptors that present in diverse cell 
types within distinct contexts. Such complexity also renders CYR61 a 
regulatory role in different physiological events, such as embryonic 
development, chondrogenesis, angiogenesis, wound healing, fibrosis and 
cancer progression 55,69,83. 
 
8.4. CYR61 in tumorigenesis and cancer progression 
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Studies in different cancers also present diversified roles of CYR61 during 
cancer progression. 
 
8.4.1. Different effects of CYR61 on different types of cancer 
 
Aberrant up-regulation of CYR61 mRNA is found in 39% of breast tumor 
samples and is associated with tumor size, more advanced stages and lymph 
node involvement 84. Another study using immunohistochemical staining on 
breast cancer tissue arrays confirmed the correlation between CYR61 protein 
expression and those clinical factors 85. Elevated CYR61 expression was 
found from the early proliferative step and was kept throughout the whole 
progression process 86. 
 
Similarly, in gastric cancer it was proposed that high CYR61 expression level 
correlated with tumor grade, lymph node metastasis and recurrence 87. In 
ovarian cancer, glioma, squamous cell carcinoma, osteosarcoma and 
pancreatic ductal adenocarcinoma, overexpression of CYR61 was found and 
correlated with tumor grade or survival of patients 88-95. Higher level of CYR61 
was also found in prostate cancer tissue compared to paired normal tissue 
around cancer lesion 96. However, CYR61 expression also correlated with 
less recurrence for patients with radical prostatectomy 97. 
 
For colorectal cancer, higher expression of CYR61 was found during cancer 
initiation and development, and was reduced in more advanced stage 98.  
 
On the other hand, CYR61 plays a tumor-suppressive role in non-small-cell 
lung cancer (NSCLC) 99,100. The expression level was downregulated 
following cancer progression, and was correlated with more advanced stage, 
poor prognosis and poor survival rate of patients and 100-102. Controversial 
correlation were proposed in endometrial cancer and hepatocellular 
carcinoma 103-106.  
 
8.4.2. CYR61 effects from experimental models 
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- Breast cancer 
 
Diverse cellular effects of CYR61 were also reported from cell-based 
functional experiments. In breast cancer cell lines, CYR61 level is significantly 
elevated in more malignant cells (i.e. MDA-MB-231, HS578T) among the 
others 84,107. Ectopic expression of CYR61 caused estrogen-independent 
growth of the estrogen-dependent beast cancer cell line MCF-7 108. MCF-7 
cells with stable CYR61 expression acquired enhanced the ability to form 
colonies under anchorage-independent conditions and promoted the 
development of vascularized tumors in nude mice through the activation of 
αvβ3 integrin 108,109, indicating the promoting role of CYR61 in tumorigenesis. 
In addition, CYR61 protected cells from apoptosis induced by various anti-
cancer drugs through integrin αvβ3-mediated ERK1/2-MAPK pathway and NF-
κB-mediated upregulation of XIAP (inhibitor of apoptosis protein) expression 
110,111. Experiment in which selected domains of CYR61 were deleted, 
demonstrated critical roles for the second and fourth modules in migration and 
invasion mediated by CYR61 86.  
 
 - Gastric cancer 
 
In gastric cancer, CYR61 promoted cancer cell migration and invasion 
through integrin αvβ3/NF-κB/COX2 and HIF1-α/PAI-1 pathways 87,112. CYR61 
also up-regulated the expression of CXCR1/CXCR2 through integrin 
αvβ3/Src/PI3K/AKT pathway to facilitate transendothelial migration and 
intravasation of gastric cancer cells 113. Through integrin α2β1, CYR61 
promoted dissemination and nodule formation of gastric cancer cells in the 
peritoneal cavity of mice 114. 
 
 - Ovarian cancer 
 
In ovarian cancer cell lines, CYR61 overexpression promoted cell proliferation 
and resistance to the anti-cancer drug cisplatin 88.  The chemoresistance is 
achieved by inhibiting caspase 3 activity 115. In addition, CYR61 also confers 
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resistance to apoptosis induced by carboplatin, a cisplatin analogue, by 
regulating the expression of Bcl-2 family proteins, NF-κB, and p53 through the 
activation of the AKT pathway 116. 
 
 - Glioma 
 
In glioma, CYR61 acts as a downstream mediator of GPCR signaling 
pathways, including thrombin receptor/RhoA-induced cell proliferation, and 
S1PR-mediated cell invasion 63,117. CYR61 was also required for HGF-
regulated cell growth and migration 90. Overexpression of CYR61 promotes 
cell growth through PI3K/AKT-induced GSK3β phosphorylation and the β-
catenin/TCF/Lef pathway, and generated larger and more vascularized 
tumors 89. 
 
 - Squamous cell carcinoma 
 
Ectopic expression of CYR61 in human oral squamous cell carcinoma (SCC) 
enhanced cell growth, cell motility and in vivo tumor development 92. By using 
blocking antibodies and chemical inhibitors, Chuang et al. showed that 
CYR61-improved cell migration was mediated through integrin 
(αvβ3/ α6β1)/FAK/ERK and NF-κB-induced expression of MMP-3 118. 
Interestingly, secreted CYR61 accelerated SCC collective cell migration and 
invasion through both autocrine and paracrine routes, providing a model of 
invasive sheet formation at the tumor border 119. 
 
 - Osteosarcoma 
 
CYR61 expression was found correlated with tumor grade in human 
osteosarcoma. Consistently, in vitro apoptosis, migration, invasion and in vivo 
metastasis were also related to CYR61 expression levels. It is noteworthy that 
its contribution to enhanced metastasis was mainly due to increased size of 
metastatic nodules 95,120. Recently, an intracellular binding protein of CYR61, 
Caprin-1, was identified in cytoplasmic stress granules. Overexpression of 
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Caprin-1 resulted in enhanced cell growth, inhibition of apoptosis, increased in 
vivo tumor growth and lung metastasis 121. However, it is still not clear 
whether CYR61 cooperates with Caprin-1 during tumor progression. 
 
 - Pancreatic cancer 
 
Haque et al. showed that CYR61 enhanced cell growth, cell migration and 
tumorigenicity of pancreatic cancer cell lines by promoting EMT and stemness 
94. Through the interaction with integrin αvβ3, CYR61 activated Notch-1 
signaling and inhibited degradation of Notch intracellular domain, thereby 
trans-activated Sonic Hedgehog (SHh) pathway and enhancing cell migration 
122. 
 
 - Prostate cancer 
 
Like in breast cancer cell lines, high level of CYR61 was found in PC3 and 
Du145 compared to the less aggressive cell lines LnCap and 22RV1, 
consistent with the observations in human prostate cancer 96,123. CYR61 
supported cell proliferation, colony formation in soft agar and subcutaneous 
tumor growth of prostate cancer, and sensitized cells to TRAIL-elicited 
apoptosis through PKC activation 123,124. CYR61 promoted cell migration by 
regulating Rac1 and focal adhesion formation, and conferred capability to 
form metastatic lesions in lung 123. 
 
 - Colorectal cancer 
 
By modulating expression level in colon cancer cell line, CYR61 was shown to 
regulate cell invasion and lung metastasis formation through cooperation with 
integrin αvβ5 125. 
 
 - Lung cancer 
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Besides the tumor-promoting role observed in most types of cancer, CYR61 
was also shown to act as a tumor suppressor in lung cancer. The suppressive 
mechanism of CYR61 to tumor growth in vitro and in vivo involves β-
catenin/c-Myc/ p53-regulated cell cycle arrest 99,126. However, the role of 
CYR61 in other cellular functions was not addressed. 
 
 - Endometrial cancer 
 
Although Chien et al. showed that CYR61 expression suppress tumor growth 
through expression of pro-apoptoitc proteins and elevated caspase-3 activity, 
there was another report claiming that CYR61 expression, together with 
lymph node metastasis, could be used to categorize cancer patients and 
predict 5-year survival rate. Therefore, more investigations need to be done to 
confirm the role of CYR61 in endometrial cancer 103,104. 
 
 - Hepatocellular carcinoma 
 
The role of CYR61 in hepatocellular carcinoma is full of controversy from both 
clinical and laboratorial data. While Feng et al. showed that expression of 
CYR61 reduced cell growth rate through p53 regulation 106, increased cell 
adhesion and slowed down cell migration and invasion, another report 
suggested a growth promoting role of CYR61 both in vitro and in vivo 105. 
 
 
8.5. CYR61 in cancer metastasis 
 
Among all the reports about CYR61 in different types of cancer, there are only 
a few investigations about the role of CYR61 during metastasis development. 
In most of studies, the pro-metastatic ability was proposed based on the 
ability of CYR61 to enhance invasion in vitro. One study based on the 
orthotopic intratibial injection of osteosarcoma cells demonstrated enhanced 
spontaneous lung metastasis formation by CYR61-overexpressing cells 95. 
Another study reported that a monoclonal CYR61 antibody could block lymph 
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node metastasis in a footpad tumor inoculation model 127. By injecting tumor 
cells through the tail vein, Sun et al. demonstrated that overexpression of 
CYR61 enhanced prostate cancer cell metastasis while downregulation of 
CYR61 suppressed the growth of metastatic foci in bone, lung and the 
peritoneal cavity 123. 
 
We have previously reported that tumors growing in a pre-irradiated stroma 
were selected for tumor cell variants with stronger invasive and metastatic 
abilities compared to tumors growing in a non-irradiated environment. This 
effect was associated with the development of strong tumor hypoxia 
secondary to radiation-impaired angiogenesis. CYR61 was upregulated in 
invasive and metastatic cells, and was found to contribute to invasion and 
metastasis through cooperation with αvβ5 integrin 125. However, the detailed 
regulatory mechanism by which CYR61 promotes metastasis was not 
addressed. 
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Aim of the study 
 
The aim of my thesis work was to investigate the role of CYR61 in breast 
cancer metastasis formation and to unravel the possible cellular and 
molecular mechanisms involved.  
 
The rationale for the study were, firstly, the previous observation of the 
laboratory that CYR61 promotes invasion and metastasis of cancers growing 
in a pre-irradiated microenvironment and, secondly, the shorter disease free 
and overall survival of breast cancer patients expressing elevated levels of 
CYR61 in their primary tumors. 
 
To address this question I have used a combination of in vivo and in vitro 
cellular and molecular approaches, in particular an orthotropic model of 
metastatic breast cancer.  
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Results 
 
Silencing of CYR61 expression in human breast cancer cell line MDA-
MB-231 
 
To investigate the role of CYR61 in breast cancer metastasis, we first 
analyzed CYR61 expression level in four human breast cell lines: MCF7, 
MCF10A, MDA-MB-231 and MDA-MB-468. Among the four cell lines, 
MCF10A is a cell line isolated from a fibrocystic patient and has no 
tumorigenic ability. MCF7, MDA-MB-468 and MDA-MB-231 are tumorigenic, 
but only MDA-MB-231 efficiently forms metastasis and has therefore been 
frequently used for the study of metastasis development in breast cancer. 
 
Consistent with other studies, we found that MDA-MB-231 showed the highest 
CYR61 protein level among all tested cells lines (Fig. 1A). Therefore, we 
knocked down CYR61 expression in MDA-MB-231 cells by stable shRNA 
expression (Fig. 1B). To further consolidate our results, we established 
additional MDA-MB-231 cell lines with silenced CYR61 expression by using 
an inducible shRNA system. Two different sequences of shRNAs targeting 
CYR61 were tested and the combination of these 2 shRNAs was then used to 
obtain the highest silencing efficiency. After puromycin selection, resistant 
cells were treated with 2µg/mL of doxocyclin (Dox) to induce the expression of 
shRNA. Time course induction experiments were done in order to 
characterize and validate the silencing efficiency (Fig. 1C). Total RNA was 
extracted from MDA-MB-231 cells at different time points and the level of 
CYR61 mRNA following Dox treatment was determined by qPCR (Fig. 1C). 
CYR61 mRNA level started to decrease 1 day after initiation of treatment 
compared with non-silencing control (NS), and reached the lowest values 
from the 3rd day of Dox treatment on. The level of CYR61 protein started to 
show a dramatic decrease from Day 3 on upon Dox treatment (Fig. 1D). The 
silencing effects of both constitutive and inducible shRNA systems were 
maintained for at least few months (data not shown). 
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In vivo studies of the capability of CYR61 to form metastasis:  
 
Silencing CYR61 in primary tumors grown in pre-irradiated mammary fat 
pads reduces spontaneous lung metastasis formation 
 
We have previously reported that tumors growing subcutaneously in pre-
irradiated stroma express higher level of CYR61 compared to tumors growing 
in normal, non-irradiated stroma and that are more metastatic. We then 
showed that CYR61 is directly involved in enhanced metastasis formation of 
tumors growing in a pre-irradiated stroma 125. To better mimicking the tumor 
microenvironment and to mirror a clinically-relevant condition, we used an 
orthotopic model of breast cancer and injected NS and CYR61 knockdown 
(KD) MDA-MB-231 cells into pre-irradiated mammary fat pads (MFP) of 
immune deficient NSG mice. One month after injection, mice were 
euthanatized and the primary tumors and lungs were fixed and embedded in 
paraffin for section (Fig. 2A). Immunohistochemical staining of human 
vimentin was used to determine the formation of metastasis in lung (Fig. 2B). 
 
Consistent with our previous findings, CYR61 expressing cells developed 
more metastatic colonies in lung (Fig. 2B, quantification in Fig. 2D). With 
CYR61 expression, NS cells formed bigger tumor masses than in the CYR61 
KD group (Fig. 2C). Moreover, bigger metastases were found in the lung 
sections of NS group of mice (Fig. 2B). The results suggest that CYR61 
provides survival advantages for cancer cells growing in pre-irradiated 
orthotopic microenvironment and increased ability to metastasize to the lung.  
 
 
CYR61 silencing in primary tumors reduces spontaneous lung 
metastasis formation 
 
These results raised the question of whether CYR61 might also promote 
metastasis formation during the natural course of breast cancer progression. 
To address this question we orthotopically injected NS and CYR61 
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knockdown (KD) MDA-MB-231 cells into non-irradiated MFP of immune 
deficient NSG mice to generate primary tumors that spontaneously 
metastasize to the lung. One month after injection, mice were euthanatized 
and the primary tumors and lungs were fixed and embedded in paraffin for 
sectioning (Fig. 3A). Immunohistochemical staining of CYR61 in primary 
tumors confirmed the efficiency of knockdown in vivo (Fig. 3B). Human 
vimentin staining was used to determine the formation of metastasis in lung 
(Fig. 3D).  
 
Although CYR61 was reported to promote cell proliferation and tumor growth 
in some experimental models as well as in our irradiation model, the size of 
primary tumors showed no difference between NS and KD groups (Fig. 3C). 
However, mice in the NS group developed significantly more metastasis 
colonies in the lung as detected by quantification of human vimentin staining 
(Fig. 3D, in Fig. 3E). The metastasis index, which reflects metastasis 
formation relative to primary tumor size, further confirmed that CYR61 KD 
cells lost partially their ability to form spontaneous lung metastasis (Fig. 3E). 
 
 
CYR61 down-regulated cells are less metastatic in an experimental 
model of metastasis 
 
The development of distant organ metastasis can be dissected into various 
steps: local invasion and escape from the primary site, entry into the blood 
circulation, survival in suspension and escape from immune surveillance, 
extravasation into distant organ, adaption to the new microenvironment and 
colonization to develop macrometastasis. To understand which one of these 
steps depends on CYR61, we injected tumor cells into the tail vein to form 
experimental metastasis, thereby bypassing the need for primary tumor 
formation, local invasion and intravasation. 
 
Twenty-eight days after tail vein injection of tumor cells, mice were 
euthanatized and lungs were fixed and embedded in paraffin for sectioning 
(Fig. 4A). Consistent with the orthotopic injection model, significantly more 
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lung metastases were observed in the NS group of mice compared with the 
KD group (Fig. 4B, quantification in Fig. 4C). Collectively, results from both 
spontaneous metastasis and experimental metastasis models indicate that 
CYR61 has limited effect on primary tumor growth under normal condition, but 
promotes breast cancer metastasis to lung. These experiments also indicate 
that CYR61 facilitates later stages of metastasis formation - survival in 
circulation, extravasation, or colonization in lung. 
 
 
CYR61 facilitates breast cancer cell extravasation into lung parenchyma 
 
In order to identify if CYR61 affects cancer cell extravasation into lung 
parenchyma or the successive colonization step in the new microenvironment, 
we conducted a short-term tail vein injection experiment, where mice were 
sacrificed 24 hours after injection. Half-million of NS or KD cells labeled with 
Green Cell Tracker were injected into tail vein of NSG mice. Twenty-four 
hours after injection, mice were anesthetized and perfused with 2%PFA/PBS 
to wash away the cancer cells remained in circulation (Fig. 5A). 
 
From the whole lung image taken under fluorescent microscope, we found 
that significantly more cancer cells were retained in lungs of the NS group of 
mice compared with KD cell-injected mice (Fig. 5B). The same result was 
obtained when we sectioned the lungs to count cancer cell colonies in lung 
(Fig. 5C, quantification in Fig. 5D). These results suggest that CYR61 
facilitates breast cancer cell extravasation into lung parenchyma during the 
fist 24-hour period after injection, and thereby affected lung metastasis 
formation. 
 
 
Delayed down-regulation of CYR61 expression does not prevent lung 
metastasis formation 
 
To further support the finding that CYR61 promoted lung metastasis formation 
by facilitating the extravasation step, we took advantage of the inducible 
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shRNA knockdown system and designed an experiment whereby CYR61 
down-regulation in vivo was induced 24 hours upon tumor cell injection, a time 
point when most tumor cells have already entered the lung parenchyma. 
 
Half-million of MDA-MB-231 cells expressing NS or CYR61 shRNA plasmid 
were injected into NSG mice through the tail vein. By the time of injection, 
these cancer cells were not yet treated with Dox and the shRNA was not 
induced. Twenty-four hours after injection, both groups of mice were fed with 
Dox water to induce the expression of shRNA, and Dox treatment was 
continued until the mice were sacrificed. Twenty-four days after injection, mice 
were euthanatized and the lungs were fixed and embedded in paraffin for 
sectioning (Fig. 6A). Total colony numbers of lung metastasis were counted, 
and the result showed that delayed downregulation of CYR61 did not impinge 
on lung metastasis formation (Fig. 6B, quantification in Fig. 6C). 
 
Overall, these in vivo data indicate that the expression of CYR61 promotes 
lung metastasis of breast cancer cells though an effect occurring within the fist 
24 hours following their injection into the blood, most likely involving 
facilitatied tumor cell extravasation into the lung parenchyma. 
 
 
In vitro studies of cellular functions modulated by CYR61:  
 
To extravasate into secondary organs, cancer cells have to adhere first to the 
endothelium and then transmigrate through the vessel wall, starting with the 
endothelial barrier. At the same time, cancer cells have to escape from cell 
death induced by loss of cell-matrix adhesion signals (anoikis) before they 
could successfully reach the proper matrix in the new microenvironment. 
 
To further dissect which of these steps are promoted by CYR61 we did in vitro 
validation experiments to analyze the effect of CYR61 on various cellular 
functions, including cell adhesion, spreading, migration, transendothelial 
migration, proliferation and colony formation under anchorage-independent 
condition. 
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CYR61 affects MDA-MB-231 cell spreading but has minimal effects on 
cell adhesion to extracellular matrix proteins 
 
Non-silencing (NS) and CYR61 KD cells were trypsinized and plated in 
matrix-pre-coated 96-well plates for adhesion for 15 minutes, 30 minutes, 45 
minutes and 1 hour. Although in some previous publications, CYR61 was 
described to enhance cell adhesion, we found only limited effect of CYR61 
silencing on adhesion. Both cell lines efficiently adhered to collagen I and 
fibronectin, and cell adhesion reached plateau already in 15 minutes for cells 
plated on higher matrix concentration (Fig. 7A). Although it seems that NS 
cells adhere more efficiently to collagen I and fibronectin, differences between 
the two cell lines were minimal with a tendency of NS cells to adhere better to 
laminin than KD cells. Overall, CYR61 induced only limited adhesion 
advantage on adhesion to extracellular matrix, suggesting that this might not 
be a main mechanism responsible for cancer cell extravasation in vivo. 
 
In addition, we also analyzed the spreading ability of both cell lines on tissue 
culture plates. Cells were seeded on plates in serum-free medium for up to 24 
hours. Four hours after plating, NS cells started to extend their protrusions 
and spread, and this phenomenon became more evident at later time points 
(Fig. 7B). In contrast, CYR61 silenced cells had a clearly retarded spreading, 
still observable at 24 hours after plating.  
 
 
CYR61 promotes MDA-MB-231 cell migration and transendothelial 
migration 
 
As cell spreading is a considered as a surrogate of cell migration, we 
performed migration assays to study the effect of CYR61 on cellular mobility, 
including scratch wound assay, transwell migration and transendothelial 
migration. 
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Both NS and KD cells were cultured in complete medium until they reached 
100% confluence. Scratches with identical width were made using pipet tips 
and the media was replaced immediately thereafter in order to remove floating 
cells. The scratched areas were photographed every hour by timelapse 
microscopy to monitor cell migration and wound closure (Fig. 8A). The 
distance between two edges of the scratch was determined and migration 
velocity was calculated (Fig. 8B). Total 7 spots from 3 different scratches for 
each cell line were recorded. As the result showed in Figure 8B, NS cells 
migrated significantly faster than CYR61 KD cells. 
 
To validate the result from the scratch wound assay, we conducted another 
migration assay by using the Transwell system. Forty thousand cells were 
seeded in the upper chamber of Transwell inserts and were allowed to 
migrate to the bottom part for 8 hours. At the end of the experiment, cells that 
remained in the upper part of the insert were carefully removed with cotton 
swabs. Cells that migrated to the other side of insert membrane were fixed 
and stained with crystal violet (Fig. 8C). Three areas per insert were chosen 
randomly and photos from total 9 areas were used to quantify numbers of 
migrated cells (Fig. 8D). The results demonstrated that NS cells have stronger 
migratory ability than CYR61 KD cells, consistent with the results from scratch 
assay. 
 
Since extravasation across the vessel wall also implicates a transmigration 
step through the endothelial layer, we tested the ability of cancer cells to 
migrate through confluent layer of endothelial cells in vitro. Human umbilical 
vein endothelial cells (HUVEC) were grown on the upper part of the Transwell 
membrane until they reached 100% confluence. Then, NS and CYR61 KD 
cells expressing RFP were seeded into the upper chamber and were allowed 
to migrate for 12 hours. At the end of the experiment, cells remained in the 
upper compartment were carefully removed with cotton swabs. Cells that 
migrated through the endothelial monolayer and reached the bottom side of 
the insert membrane were fixed and photographed by fluorescent microscopy 
(Fig. 8E). Nine areas per insert were chosen randomly and photographs from 
a total of 27 areas were used to quantify the percentage of area occupied by 
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migrated cells (Fig. 8F). Results from these experiments demonstrated that 
NS cells migrated more efficiently across the endothelial monolayer compared 
to silenced cells. 
 
 
CYR61 enhances colony formation under anchorage-independent 
condition but has limited effect on cell proliferation under 2D conditions 
 
When travelling in the blood from the primary tumor to a distant organ, tumor 
cells do so in the absence of adhesion to extracellular matrices. Lack of cell-
matrix interaction triggers integrin-dependent death-promoting signals in 
normally adherent cells, an event known as anoikis.  
 
To test the ability of NS and CYR61 KD MDA-MB-231 cells to survive and 
grow under anchorage-independent conditions, we suspended the cancer 
cells in soft agar and let them grow to form colonies. After two weeks, random 
areas were photographed (Fig. 9A) and both number and the size of colony  
formed by each cell line were measured (Fig. 9B). The result showed that NS 
cells formed significantly more and larger colonies compared to CYR61 KD 
cells. 
 
However, both cell lines grew to similar rates under normal, 2D culture 
conditions (Fig. 9C), suggesting that CYR61 protects cells under conditions of 
limited or absent cell adhesion and could therefore supports cell growth under 
anchorage-independent conditions. 
 
 
Expression of CYR61 protects cancer cells in suspension from 
apoptosis 
 
To collect further evidence whether CYR61 conferred resistance to anoikis, 
we kept the MDA-MB-231 cells in suspension and then stained them with 
Annexin V and near-IR dead cell marker dye. Flow cytometry analysis was 
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conducted to identify apoptotic (Annexin V positive) from viable (double 
negative) cell populations.  
 
The suspension time course clearly showed that there was an increasing 
fraction of apoptotic MDA-MB-231 cells among the CYR61 KD population, 
while in NS population the fraction of apoptotic cells remained low and steady 
throughout the whole period of the experiment (Fig. 10A-B).  
 
 
CYR61 protects cancer cells from apoptosis through β1/β3 integrin 
 
Previous studies have shown that CYR61 interacts with various integrins to 
activate cellular signaling pathways. To investigate whether CYR61 prevented 
anoikis through engagement of integrins, we first analyzed the surface level of 
CYR61 (Fig. 10C) and different integrin subunits (Fig. 10D). We confirmed 
that CYR61 shRNA decreased surface level of CYR61 protein without 
alternating surface level of integrins. 
 
Then, we treated both cell populations with functional antibodies to specifically 
block or activate integrins. Addition of a functional blocking anti-β1 integrin 
antibody in NS cells increased the fraction of apoptotic cells. In contrast, 
addition of a β3 integrin activating antibody partially rescued apoptosis in 
CYR61 KD cells (Fig. 10E). These observations suggest that the ability of 
CYR61 to confer resistance of breast cancer cells to anoikis depends on β1 
and β3 integrins. 
  
! 38 
Discussion 
 
CYR61 promotes breast cancer metastasis to the lung by 
facilitating extravasation 
 
CYR61 was shown to regulate various cellular functions including cell 
proliferation, adhesion, and migration. At tissue level, CYR61 was reported to 
contribute to the development of the vascular system, chondrogenesis, T cell 
production in thymus, wound healing, fibrosis and cancer progression 70,128-
133. Clinical studies on different types of cancer clearly revealed the complex 
role of CYR61 in cancer biology. CYR61 promoted cancer progression in 
most types of cancer, including breast, gastric, ovarian cancer, glioma, 
squamous cell carcinoma, osteosarcoma and pancreatic ductal 
adenocarcinoma. In prostate and colorectal cancers, CYR61 is more related 
to tumor initiation, since the expression level decreased in more advanced 
stages. On the contrary, a tumor-suppressing role was proposed in non-small 
cell lung cancer, endometrial cancer and hepatocellular carcinoma. The 
apparent dual role of CYR61 (i.e. tumor promotion vs tumor suppression) was 
confirmed by many cell-based experiments. It was suggested that the 
complexity is due to the heterogeneous cellular context in different cell types, 
including binding to different cell surface receptors, in particular integrins, and 
activation of diverse signaling pathways in different cell types. Importantly, 
most of the published experimental reports investigating the in vivo role of 
CYR61 during cancer progression focused on primary tumor development, 
especially primary tumor growth, but did not address the role of CYR61 on 
metastasis formation.  
 
Considering that metastasis is responsible for over 90% of cancer-related 
patients’ death, research efforts should focus on the study of the mechanisms 
of multistage metastasis formation in order to improve cancer therapies. For 
example, based on the linear progression model of metastasis formation, 
cancer dissemination occurs late during tumor progression and therefore 
metastatic lesions are considered to be formed by the same type of tumor 
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cells as primary lesion and therefore treated based on the characteristics of 
primary tumors. Thus, Trastuzumab is used to treat metastatic breast cancer 
based on the expression of its target (ErbB2) in primary tumor cells. However, 
the recent finding that circulating tumor cells could be released during early 
stage of tumorigenesis and have therefore much longer time to accumulate 
mutations independently of the progression of the primary tumor (i.e. the 
parallel model of metastasis progression) provides a novel perspective to 
reconsider the timing or strategy of metastasis treatment 32. 
 
We previously showed that CYR61 is upregulated in tumor cells grown in pre-
irradiated stroma in a subcutaneous xenograft cancer model (i.e. mimicking 
postradiation relapses), and that expression of CYR61 promoted tumor cell 
invasion and metastasis 125. However, it remained unclear at which step 
CYR61 plays its critical role in promoting cancer metastasis. With another 
orthotopical mammary fat pad injection model, we found that 4T1 murine 
breast cancer tumor cells growing in pre-irradiated stroma developed more 
lung metastases than in non pre-irradiated fat pads 134. To understand if 
CYR61 promotes cancer metastasis under this condition, we adopted a model 
of human breast cancer by injecting human breast cancer cells (MDA-MB-
231) orthotropically in pre-irradiated mammary fat pads. With this model we 
demonstrated that silencing of CYR61 expression reduced lung metastasis 
formation. As these relapses are indeed quite rare in patients, we wondered 
whether CYR61 also plays a role in lung metastasis during the natural course 
of breast cancer progression. To address this question we used different 
models of breast cancer metastasis. 
 
First we injected non-silenced (NS) and CYR61 silenced (CYR61 KD) MDA-
MB-231 breast cancer cells orthotopically into mammary fat pads of non-
irradiated mice (Fig. 3A). Lung metastasis visualized by vimentin staining 
clearly showed that down-regulation of CYR61 reduced spontaneous 
metastasis formation (Fig. 3D-F). To avoid the influence of primary tumor 
mass and evasion from primary site and focus on the later 2 steps - 
extravasation and colonization, we injected the same number of NS and 
CYR61 KD cancer cells directly into tail vein (Fig. 4A). The NS group of mice 
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showed significantly more lung metastases compared to the KD group (Fig. 
4B-C). Similar results were obtained from 24-hour tail vein injection (Fig. 5), 
suggesting that CYR61 promotes metastasis either by facilitating 
extravasation or promoting cancer cell growth in the lungs. To discriminate 
between these two hypotheses, we delayed CYR61 silencing by inducing 
expression of NS and CYR61 shRNA 24 hours after injection. This timeframe 
was adopted from the initial time course of inducible KD efficiency (Fig. 1C). 
Result from this experiment showed that delayed CYR61 silencing rescued 
lung metastasis formation in the KD group of mice, thereby strengthening the 
hypothesis that CYR61 facilitates cancer cell extravasation rather than lung 
colonization (Fig 6).  
 
 
The first direct evidence that CYR61 promotes pulmonary 
metastasis  
 
Our work presents the first direct experimental evidence that CYR61 
promotes breast cancer metastasis to the lung. Lin et al. who used also MDA-
MB-231 cells showed that a CYR61 antibody could block lymph node 
metastasis 127. However, they inoculated cancer cells into the footpad, a 
model that does not recapitulate the biological environment for breast cancer 
development and metastasis. Moreover, although lymph node infiltration is 
generally considered as an indicator of cancer cell spreading out of primary 
site, whether these infiltrated cells could actively develop overt metastases at 
distant sites is still under debate. In fact, clinical and experimental evidence 
indicate that cancer cells may remain inert in lymph nodes. The correlation 
between lymph node infiltration and patient prognosis or survival rate also 
needs to be further analyzed. Evidence so far indicates that removal of 
metastatic lymph nodes does not significantly impact distant metastasis 
formation and survival. In our experiment, lymph node metastasis was found 
in both groups of mice and was independent of CYR61 level or lung lesion 
numbers (data not shown). 
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Besides lung, bone is another major target organ of breast cancer metastasis. 
However, we found only sporadic cases of bone metastasis in mice with 
severe lung metastasis in both groups. Considering that the MDA-MB-231 
cells already express extremely high level of CYR61, we conclude that 
CYR61 may not play a critical role during bone metastasis formation, and that 
alternative mechanisms and molecules are required. For instance, a gene set 
favoring bone metastasis formation was identified by comparing parental 
MDA-MB-231 cells and cell lines derived from bone metastasis 135. In this 
study, overexpression of IL-11, CTGF, CXCR4, and MMP-1 dramatically 
increased rate and incidence of MDA-MB-231 cell bone metastasis. 
Interestingly, CTGF also belongs to the CCN family and shares many features 
with CYR61. Like CYR61, CTGF is known to modulate diverse cellular 
functions also mainly through integrins. The functions of these two proteins 
may be overlapping or redundant by binding to the same integrin receptors. 
 
 
CYR61 enhances MDA-MB-231 cell motility but not adhesion  
 
After having demonstrated that CYR61 promotes MDA-MB-231 breast cancer 
cell metastasis to the lung by facilitating extravasation, we aimed to 
investigate more in detail how CYR61 promotes cancer cell extravasation. 
The process of extravasation could be further dissected into 3 parts: (1) tumor 
cell survival in the circulation, (2) tumor cell adhesion on endothelial cells, and 
(3) tumor cell transendothelial migration. Each step presents a hurdle for 
cancer cells in order to reach lung parenchyma. 
 
Many papers have demonstrated that CYR61 enhances cell adhesion on 
ECM proteins. However, we found very limited effect on MDA-MB-231 cells 
cell adhesion to ECM proteins by downregulating CYR61 expression (Fig. 7). 
Consistent with others’ finding, we found that CYR61 silencing decreased cell 
motility in scratch wound and transwell migration assays. Moreover, silencing 
CYR61 decreases cancer cell transmigration across an endothelial cell 
monolayer in vitro (Fig. 8).   
! 42 
 
 
CYR61 promotes anchorage-independent growth and confers 
resistance to anoikis 
 
Result from anchorage-independent colony formation assay using NS and 
CYR61 KD MDA-MB-231 cells showed that CYR61 promotes the formation of 
more and larger colonies under 3D non-adhesive conditions (soft agar assay), 
while cell growth on normal culture dishes was not different (Fig. 9). These 
data indicate that CYR61 favors cell survival under anchorage-independent 
conditions. A pro-survival effect was further investigated by keeping both NS 
and CYR61 KD cells in suspension and detecting apoptosis by Annexin V 
staining (Fig. 10). We found a clear time-dependent increase of the fraction of 
apoptotic cells in CYR61 KD cells, while in NS cells the fraction of Annexin V 
positive cells remained low. This observation is consistent with other lab’s 
finding that MDA-MB-231 cells are largely resistant to anoikis 136. Moreover, 
incubation of NS cells in suspension with anti-β1 integrin blocking antibody 
increased the percentage of apoptotic cells, while incubation of CYR61 KD 
cells in suspension with anti-β3 integrin activating antibody partially reduced 
the fraction of apoptotic cells, suggesting that integrin ligation protects cells 
from anoikis and that integrin activation partially compensate for the loss of 
CYR61. Thus CYR61 confers MDA-MB-231 cells resistance to anoikis 
through integrin β1 and β3. 
 
Anoikis is a form of apoptosis induced when adherent cells are detached from 
their substrate and lose their adequate cell-matrix interaction. Along the 
metastatic cascades, cancer cells detach from the ECM and float in blood or 
lymph. Resistance to anoikis therefore protects malignant cells from dying 
while in suspension and thereby facilitates their dissemination toward 
secondary sites 27,28. Three pathways regulating anoikis have been proposed: 
(1) intrinsic apoptotic pathway, (2) extrinsic apoptotic pathway, and (3) 
caspase-independent death signaling 28. The first two pathways rely on the 
BCL family proteins and mitochondria-dependent caspase activation. The key 
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regulator of the third pathway - Bit1 - is released from mitochondria to the 
cytosol when integrin-matrix interaction is disrupted. Cytosolic Bit1 stimulates 
the relocation of TLE1/AES heterodimer complex from nucleus to cytosol. 
TLE1 is a transcription regulator of many anoikis-related genes. Although the 
downstream genes are not characterized yet, TLE1 has been shown to 
enhance Bcl-2 activity and upregulate expression of anti-apoptotic proteins – 
HSP70 and thymosin-β 29. TLE1 proteins translocated into the cytosol 
therefore loose their transcriptional function. Cytosolic TLE1 are targeted to 
the proteasome for degradation 28,29. Interestingly, the expression pattern of 
Bit1, an effector molecule of anoikis, is opposite to the expression pattern of 
CYR61 both in vivo and in vitro. In invasive breast tumors, lower expression of 
Bit1 was found when compared with normal or ductal carcinoma in situ. 
Besides, reduced level of Bit1 was also shown in the more aggressive MDA-
MB-231 cells compared to MCF-7 cells. Silencing of Bit1 expression resulted 
in an increased amount of pulmonary metastases without affecting primary 
tumor growth 136. In addition, increased ERK2 phosphorylation was found in 
Bit1 KD cells, due to the downregulation of ERK2 phosphatase activity. ERK 
phosphorylation was proposed to support cell survival under non-adhesive 
conditions and to protect cells from anoikis 136,137. In our CYR61 KD MDA-MB-
231 cells, ERK2 phosphorylation showed no difference with NS cells in 
adherent condition, but was downregulated when cells were kept in 
suspension (data not shown). This data suggested the hypothesis that in 
MDA-MB-231 cells losing cell-matrix contact, ERK becomes de-
phosophorylated, while CYR61 reduces ERK2 de-phosophorylation possibly 
through the negative regulation of Bit1.  
 
Although there is no publication showing that CYR61 modulates ERK 
phosphatase activity or expression, findings from Mitsushima et al. showed 
that the focal adhesion (FA) protein vinexin β prevents ERK2 de-
phosophorylation by suppressing MAP kinase phosphatase-3 (MKP-3) when 
keeping cells in suspension 138. In addition, the other CCN family member, 
CTGF, has been reported to upregulate MKP-1 and enhancing cell survival of 
activated mesangial cells by inactivating p38 MAPK 139. Taken together these 
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observations suggest that CYR61 protects cells in suspension from apoptosis 
(anoikis) by interacting with integrins and sustaining ERK phosphorylation 
through the inhibition of MKP. 
 
 
CYR61 controlled cell death and cancer therapeutic 
perspectives 
 
Besides conferring resistance to anoikis, CYR61 has also been reported to 
promote cell survival and resistance against the cytotoxic effects of 
chemotherapy drugs. In the breast cancer cell line MCF-7, overexpression of 
CYR61 inhibited p53 accumulation induced by Taxol treatment, which could 
be reversed by inhibiting integrin αvβ3 ligation or ERK1/2 signaling 110. Lin et al 
further showed that CYR61 mediates resistance to apoptosis induced by 
multiple chemotherapy drugs through an integrin/NF-κB/XIAP (inhibitor of 
apoptosis protein) pathway in MCF-7 cells 111. However, in fibroblasts CYR61 
played an opposite role by regulating TNFα- and Fas-mediated apoptosis 
through ROS production, p38 MAPK activation, cytochrome c release and 
caspase-dependent apoptosis 78,79,140. These controversial data highlight the 
complex and pleiotropic functions of CYR61 and call for further work to better 
understand how CYR61 regulates cell survival. One possibility is that by 
interacting with different membrane receptors (i.e. integrins), CYR61 elicits 
distinct signaling events differentially affecting cell survival. On the other side, 
cancer cells may have already up-regulated anti-apoptotic genes or 
deregulated pro-apoptotic pathways which protect them from traditional cell 
death programs. In more aggressive tumors and cancer cell lines, they 
showed even resistance to anoikis with CYR61 expression 28,136. A better 
understanding of CYR61-regulated cell survival programs, might help to inhibit 
metastasis formation by impeding anoikis resistance, and at the same time 
counteract the development of resistance to chemotherapy.  
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Figures 
 
 
 
 
 
Figure 1. Silencing CYR61 expression in MDA-MB-231 cells. (A) 
Representative Western blot showing endogenous CYR61 protein levels in 
MCF7, MCF10A, MDA-MB-231 and MDA-MB-468 cells. (B) Western blot 
demonstrating constitutive silencing efficiency of CYR61 in MDA-MB-231 cells 
using a CYR61 targeting shRNA. NS: non-silencing, KD: CYR61 knockdown. 
(C) CYR61 mRNA level relative to NS control after doxocycline (Dox) 
treatment showing the efficiency of inducible shRNA targeting CYR61 in 
MDA-MB-231 cells. (D) Representative Western blot of CYR61 protein 
showing that the inducible shRNA efficiently silence CYR61 protein 
expression in MDA-MB-231 cells. 
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Figure 2. Silencing CYR61 in primary tumors grown in pre-irradiated 
mammary fat pads reduces tumor growth and spontaneous lung 
metastasis formation. (A) Schematic illustration of pre-irradiation orthotopic 
injection breast cancer model. MFP: mammary fat pad. IR: irradiation. (B) 
Immunohistochemical staining of human vimentin to reveal lung metastases. 
Scale bar: 500µm. (C) Primary tumor volume by weight (g). N=6 for both 
groups; *: p<0.05. (D) Quantification of lung metastasis colony numbers. N=6 
for both groups; *: p<0.05. 
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Figure 3. Silencing CYR61 in primary tumors reduces spontaneous lung 
metastasis formation. (A) Schematic illustration of the protocol of the 
orthotopic injection model. (B) Immunohistochemical staining of CYR61 
showed the knockdown efficiency in vivo. Scale bar: 100µm. (C) Primary 
tumor volume by weight (g). N=6 for both groups; ns: none significance. (D) 
Immunohistochemical staining of human vimentin demonstrates lung 
metastases. Scale bar: 500µm. (E) Quantification of lung metastasis colony 
numbers. N=6 for both groups; *: p<0.05. 
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Figure 4. CYR61 down-regulated cells are less metastatic in an 
experimental model of lung metastasis. (A) Schematic illustration of the 
protocol of the tail vein injection model. (B) Immunohistochemical staining of 
human vimentin demonstrates lung metastases. (C) Quantification of lung 
area occupied by metastatic tumors. N=7 for both groups; **: p<0.01. 
 
  
! 49 
 
 
 
Figure 5. CYR61 facilitates breast cancer cell extravasation into the lung 
parenchyma. (A) Schematic illustration of the protocol of the 24-hour tail vein 
injection model. (B) Images of the lung surface taken immediately post-
injection (0 hour) show that equal amount of cancer cells labeled with Green 
Cell Tracker CMFDA were injected. After 24 hours, images of the lung surface 
demonstrate that significantly more NS cancer cells were present in the lungs. 
(C) Images from 7µm of lung sections obtained 24 hours post-injection. Scale 
bar: 250µm. (D) Quantification of cancer cell colony numbers per field from 
(C). N=9 for both groups; ***: p<0.005. 
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Figure 6. CYR61 does not affect breast cancer lung metastasis formation 
once cells are extravasated. (A) Schematic illustration of the protocol of 
delayed down-regulation of CYR61 in the tail vein injection model. (B) HE 
staining of lungs reveals metastasis formation. (C) Quantification of lung 
metastasis colony numbers from (B). N=6 for both groups; ns: none 
significance. 
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Figure 7. CYR61 affects MDA-MB-231 cell spreading but has minor 
effects on cell adhesion to extracellular matrix proteins. (A) Silencing 
CYR61 in MDA-MB-231 cells show minor reduction on adhesion to collagen I 
and laminin. Adhesion on fibronectin was not affected. Adherent cells were 
stained with crystal violet (CV) and the absorbance of eluted CV measured at 
595 nm was used for quantification. Col: collagen I; Fib: fibronectin; Lam: 
laminin. **: p<0.01; ****: p<0.001. (B) CYR61 silenced cells showed retarded 
spreading under serum-free condition.  
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Figure 8. CYR61 enhances MDA-MB-231 cell migration and 
transendothelial migration. (A-B) CYR61 KD MDA-MB-231 cells migrated 
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slower in a scratch wound assay. Quantification of migration velocity 
(µm/hour) is shown in (B). A total of 7 spots from 3 scratches were monitored. 
***: p<0.005. (C-D) Reduced migration of CYR61 KD MDA-MB-231 cells in a 
Transwell migration assay. Migrated cells were fixed and stained with crystal 
violet. Quantification of migrated cells per field is shown in (D). A total of 9 
random fields were chosen from 3 transwell inserts. ****: p<0.001. (E-F) 
Reduced migration of CYR61 KD MDA-MB-231 cells in a transendothelial 
migration assay. RFP-expressing cancer cells that migrated across the 
endothelial monolayer were photographed and quantified in (F). A total 27 
random fields were analyzed from 3 Transwell inserts. *: p<0.05. 
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Figure 9. CYR61 enhances colony formation under anchorage-
independent conditions. (A) CYR61 silenced MDA-MB-231 cells formed 
smaller and fewer colonies in soft agar. Scale bar: 250µm. (B) Quantification 
of colony size and colony number per field from (A). Total 12 random fields 
from triplicate wells, and 3 focusing depth in each field were analyzed. ****: 
p<0.001. Representative data from one of three independent experiments are 
shown. (C) 2D proliferation assay showed no difference between NS and 
CYR61 silenced cells. 
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Figure 10. CYR61 confers resistance to anoikis in MDA-MB-231 cells. (A) 
NS and CYR61 KD MDA-MB-231 cells kept in suspension from 0 to 8 hours 
were stained with Annexin V-Alexa 488 and near-IR dead cell dye to 
distinguish viable, apoptotic and dead cell populations. (B) Quantification of 
the fraction of apoptotic cells of both NS and CYR61 KD populations during 
suspension time course. (C) CYR61 cell surface level. CYR61 KD cells have 
reduced CYR61 expression at the cell surface. (D) Integrin expression on NS 
and CYR61 KD cells. No significant changes in integrin profiles were 
observed among the two cell lines. (E) Incubation of β1 integrin blocking 
antibody with NS cells and β3 integrin activating antibody with CYR61 KD 
cells partially rescue resistance to anoikis mediated by CYR61. 
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Materials and Methods 
 
Cell culture media, reagents proteins and antibodies 
 
DMEM, DMEM/F12, M199, penicillin/streptomycin and trypsin were 
purchased from Gibco (NY, USA), and fetal bovine serum (FBS) was from 
Eurobio (Les Ulis, France). Doxocycline, 3,3’-diaminobenzidine (DAB) tablets, 
bovine placenta fibronectin and mouse laminin were obtained from Sigma-
Aldrich (Buochs, Switzerland). TriPure Isolation Reagent was product of 
Roche (Mannheim, Germany), and the SuperScript First-Strand Synthesis Kit, 
Green Cell Tracker CMFDA, Annexin V and LIVE/DEAD Fixable Near-IR 
Dead Cell Stain Kit were obtained from Invitrogen Life Technologies (Basel, 
Switzerland). KAPA SYBR FAST Universal 2x qPCR Master Mix kit was 
purchased from Kapa Biosystems (Boston, USA). Luminata Western HRP 
Substrate was bought from Millipore (Billerica, MA). Growth factor-reduced 
Matrigel and rat tail collagen I were purchased from Ceton-Dickinson (Basel, 
Switzerland). Luciferin was from Biosynth (Staad, Switzerland). Mouse on 
Mouse (M.O.M.) blocking reagent, Avidin/Biotin blocking kit, Vectastain ABC 
kit and biotinylated horse anti-mouse IgG were obtained from Vector 
Laboratories (Burlingame, USA). Vimentin antibody, goat anti-mouse IgG-
HRP and goat anti-rabbit IgG-HRP were from DAKO (Glostrup, Denmark), 
and the CYR61 antibody was from Santa Cruz (TX, USA). 
 
Cell culture 
 
HEK293T, MCF-7, MDA-MB-468 and MDA-MD-231 cells were grown in 
DMEM supplemented with 10% FBS, and 1% penicillin/streptomycin. Special 
DMEM/F12 supplemented with 10% horse serum, 20 ng/mL EGF, 0.5 mg/mL 
hydrocortisone, 100 ng/mL cholera toxin, 10 µg/mL insulin and 1% 
penicillin/streptomycin was used to grow MCF-10A. 
 
Human umbilical vein endothelial cells (HUVEC) were grown in M199 with 
10% FBS, 1% penicillin/streptomycin, 1 µg /mL hydrocortisone, 5 µg /mL 
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EGF, 5 µg/mL bovine pituitary extract, and 25 unit/mL heparin. Culture plates 
for HUVEC were pre-coated with 1% gelatin for 30 min. HUVECs between 3rd 
to 7th passages were used for experiments. For subculture, cells were 
trypsinized with 0.05% trypsin-EDTA and passaged every 2-3 days. All 
cultures were kept at 37°C with 5%CO2. 
 
Lentivirus production and transduction 
 
All shRNA vectors (pLKO.1 for constitutive knockdown and pTRIPZ for Tet-On 
inducible knockdown) were obtained from Open Biosystems (Huntsville, AL). 
Lentiviruses were produced by co-transfection of shRNA sequence-containing 
vectors with pSD11 (VSV-G, viral envelope) and pSD16 (packaging construct) 
into HEK293T cells by calcium phosphate transfection method. Cells were 
replaced with fresh medium after overnight incubation, and the virus-
containing supernatant media were collected, filtered through 0.45µm filters 
and aliquoted for virus infection. 
 
For transduction, MDA-MB-231 cells were seeded into culture dishes one day 
before transduction to reach 70% confluence before exposure to the 
lentivirus. Lentivirus-containing supernatant was supplemented with 10% 
fresh culture DMEM and 8 µg/mL polybrene and incubated with cells for 6-8 
hours. Afterwards, medium was replaced again with fresh culture medium and 
the cells were kept for 2 days before puromycin selection. Over 90% of cells 
were successfully transduced and resulted in stable cell lines. To induce the 
expression of pTRIPZ inducible shRNA system, doxocycline was added to 
culture medium of puromycin-selected cells with a concentration of 2 µg/mL. 
Except for specific time course experiment, cells with inducible shRNA system 
were treated with doxocycline for at least 3 days before conducting 
experiments. The knockdown efficiency of each shRNA was validated by 
qPCR and immunoblot for mRNA and protein expression. 
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Real-time quantitative PCR 
 
Total RNA was isolated from cells lysed with TriPure Isolation Reagent 
following manufacturer’s instruction. RNA concentration was measured by 
Nanodrop spectrophotometer (Wilmington, USA). For complementary DNA 
synthesis, up to 5 µg of total RNA was mixed with Superscript First Strand 
Synthesis Kit for reverse transcription. cDNA were diluted 1:20-1:100 for 
conducting real-time PCR by using KAPA SYBR FAST Universal 2x qPCR 
Master Mix kit on the Step One Plus Real-Time PCR System (Applied 
Biosystems). Dissociation curve of each reaction was checked to determine 
the purity of PCR end products. Relative Ct values of target genes to house-
keeping gene (GAPDH) were calculated to compare the expression level 
between samples. All qPCR reactions were done in duplicate, and the data 
from one of three independent repeats was shown. Primer sequences were 
as following: 
CYR61 forward: 5’- ACGCTGGATGTTTGAGTGTG 
CYR61 reversed: 5’- TGTAGAAGGGAAACGCTGCT 
GAPDH forward: 5’- GGACCTGACCTGCCGTCTAG 
GAPDH reversed: 5’- CCACCACCCTGTTGCTGTAG 
 
Immunoblotting 
 
Cells were lysed with 1% NP-40 lysis buffer with protease inhibitors. Twenty 
µg of total proteins were boiled with 6x sample buffer at 95°C for 5 minutes 
and resolved by 10% SDS-PAGE with 1x running buffer (25mM Tris, 192mM 
glycine, 0.1% SDS). After electrophoresis, SDS-PAGE was transferred to 
Immobilon-P Transfer Membrane (Milipore, Zug, Switzerland) with 1x transfer 
buffer (25mM Tris, 192mM glycine, 20% methanol) under 250mA for 4 hours. 
Membranes were blocked by 5% BSA/1x TBSt (10mM Tris, 150mM NaCl, 
0.1% Tween 20, pH7.4) at room temperature for 2 hours. Primary antibodies 
and peroxidase-conjugated secondary antibodies were diluted to 1:1000 and 
1:4000 in 1% BSA/1x TBSt, incubated with membranes at room temperature 
for 1.5 hours. After antibody incubation, the blots were quickly rinsed by 1x 
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TBSt for three times, and washed by 1x TBSt for three times, 15 minutes per 
wash time. Blots were incubated with Luminata Western HRP Substrate for 3 
minutes, and the chemiluminescent signal was detected by exposing blots to 
X-Ray films. 
 
In vivo tumor growth and metastasis formation  
 
Eight-weeks-old of NSG female mice (animal facility, CIL, University of 
Lausanne, Epalinges, Switzerland) were used for all in vivo tumor growth and 
metastasis formation studies. For orthotopic primary tumor formation, one 
million of MDA-MB-231 luciferase-expressing cells were resuspended in 40 
µL serum-free DMEM and mixed with 10 µL Matrigel were injected into the 
right 4th mammary fat pad. Formation of spontaneous metastasis was 
indicated by bioluminescence signal obtained from the Caliper IVIS Lumina II 
(PerkinElmer, USA) following luciferin i.p. injection. Half million of MDA-MB-
231 cells in 100 µL PBS was injected through tail vein to generate 
experimental metastasis. At the end of the experiments, mice were 
anaesthetized and perfused with 2% paraformaldehyde (PFA)/PBS. Primary 
tumors and lungs were fixed by 4% PFA overnight and then embedded in 
paraffin. Lungs from 24-hour tail vein injection experiment were embedded in 
OCT for cryosection. All animal experiments were done according to national 
ethical guidelines and were authorized by the veterinary service of Canton 
Fribourg. 
 
To quantify metastasis in lung, sections from 2 to 4 different planes with 200 
µm distance between each plane were stained by HE or vimentin IHC. Total 
number of metastasis nodules from the whole section was counted under light 
microscope (Zeiss, Germany). To determine the lung area occupied by 
metastasis, five random areas per section were photographed, and the 
average values for each mouse was calculated. Metastasis index was 
calculated by normalizing the mean values of metastatic foci number by 
primary tumor weight. 
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Immunohistochemistry 
 
Paraffin blocks were cut into 4 µm thin sections. After deparaffinization and 
dehydration, sections were heated in Tris-EDTA (pH 10) buffer for 20 minutes 
and slowly cooled down to retrieve antigen epitopes. To quench endogenous 
peroxidase, sections were incubated with 3% H2O2 for 10 minutes. Mouse on 
Mouse (M.O.M.) blocking reagent was adopted to reduce non-specific binding 
for vimentin staining. Vimentin antibody and biotinylated goat anti-mouse 
secondary antibody were diluted 1:200 and 1:800 respectively. Following the 
incubation of Vectastain ABC kit, the specific immunostaining from antibody-
peroxidase complex was visualized with the DAB peroxidase substrate. 
Sections were then counterstained with hematoxylin and mounted for 
examination. 
 
Adhesion assay 
 
Collagen I, fibronectin, and laminin were coated at different concentrations (1, 
2.5, and 5 µg/mL) on 96-well plates at 37°C for 3 hours followed by blocking 
with 1% BSA at 4°C overnight. NS and CYR61 KD cells were trypsinized, 
resuspended in serum-free DMEM, and allowed to adhere on coated plates 
(4x104 cells / 100µL / well) for different time period (from 15 minutes to 40 
minutes) at 37°C. At the end of adhesion, unattached cells were washed 
away by rinsing with PBS. Adhered cells were fixed by 4% PFA for 10 minutes 
and stained with crystal violet. Specific binding to each ECM protein was 
determined by quantification of absorbance at 595 nm wavelength in a 
multiwall plate reader (Modulus II microplate reader, Turner Biosystems). 
Results were analyzed by Prism, and the representative results from three 
independent experiments are shown. 
 
Spreading assay 
 
Cells were trypsinized and resuspended in serum-free DMEM. Equal amount 
of NS and CYR61 KD cells were plated under serum-free conditions. Cell 
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spreading was monitored and photographed by phase contrast microscopy 
every 2 hours. Representative data from one of the three independent 
experiments are shown. 
 
Scratch wound migration assay 
 
MDA-MB-231 cells were grown to 100% confluent in 6 well plates. Scratches 
were made by micro-pipet tips, and the medium was immediately replaced 
with 5% FBS-containing DMEM to remove suspended cells. The closure of 
scratches was monitored by timelapse microscopy for 24 hours. In total, 
seven spots from three scratches were recorded for each cell line, and the 
migration velocity was presented as migrated distance (µm) per hour. 
Representative data from one of the three independent experiments was 
shown. 
 
Transwell migration assay 
 
The Transwell inserts (8µm pore size, Becton-Dickinson, Bedford, MA) were 
pre-incubated with serum-free DMEM at 37°C for 30 minutes before use. 
Then, 700 µL DMEM containing 5%FBS was carefully loaded to the lower part 
of chamber, and 4x104 cells in 200µL serum-free DMEM was added to the 
upper part of chamber. Cells were allowed to migrate through the membrane 
for 8 hours at 37°C. Non-migrated cells still in the upper part of chamber were 
carefully removed by cotton swabs. The membrane was then fixed with 4% 
PFA for 10 minute to fix the cells migrated on the lower side of the membrane, 
followed by crystal violet staining for 10 minutes. Three random fields were 
chosen from each insert and total 9 fields were photographed to quantify the 
numbers of migrated cells. Representative data from one of the three 
independent experiments are shown. 
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Transendothelial migration assay 
 
HUVECs (5000cells / insert) were plated on gelatin pre-coated Transwell 
inserts (8µm pore size) and cultured for 2 days to reach 100% confluence. 
Before experiments, medium in the lower chamber was replaced with 700 µL 
M199 containing 5% FBS, and medium in the upper chamber was replaced 
with 100 µL serum-free M199. RFP-expressing NS and CYR61 KD MDA-MB-
231 cells were trypsinized, and 4x104 cells in 100 µL serum-free DMEM was 
loaded to each chamber. Transendothelial migration was allowed for 12 hours 
at 37°C. At the end of the experiment, HUVECs and non-migrated MDA-MB-
231 cells in the upper part of the chamber were carefully removed by cotton 
swabs. The membrane was then fixed with 4% PFA for 10 minute to fix the 
cells migrated on the lower side of the membrane and migrated cells were 
visualized under fluorescent microscope. Nine random fields from each insert 
were photographed. Total 27 fields were analyzed by ImageJ to quantify the 
area covered by migrated cells. Representative data from one of the three 
independent experiments are shown. 
 
Proliferation assay 
 
Cell growth rate was calculated from surface area covered by cells optically 
determined by IncuCyte FLR (Essen Bioscience, USA). MDA-MB-231 cells 
(12.5x104 cells / well) were plated in a 6-well plate at 5% initial confluence and 
cultured until the confluence reached 100%. Total 18 spots from 2 wells per 
cell line were monitored. Representative data from one of the three 
independent experiments are shown. 
 
Anchorage-independent cell growth assay 
 
Six-well plates were pre-coated with 0.6% agar in DMEM supplemented with 
5% FBS. Cells (2x104 cells / 2mL / well) mixed with 0.3% agar in DMEM 
supplemented with 5% FBS were plated on top. DMEM with 5% FBS was 
added to the wells and replaced with fresh medium every 2 days. After 2 
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weeks, colonies were stained with 0.005% crystal violet. Twelve random fields 
from triplicate wells were photographed with 3 different focuses to calculate 
both colony number and colony size. Colony size is categorized into 3 groups 
according to the diameter: <50µm, 50-100µm, 100-200µm, and >200µm. 
Representative data from one of the three independent experiments are 
shown. 
 
Anoikis assay 
 
Cells were trypsinized and 3x105 cells were kept in FACS tubes in serum-free 
DMEM for the indicated periods of time. Different integrin blocking or 
activating antibodies were co-incubated with cells throughout the time being in 
suspension. At the end of experiment, cells were stained with Annexin V-
Alexa 488 and LIVE/DEAD Fixable Near-IR Dead Cell Stain Kit. The apoptotic 
(Annexin V positive) and dead cell (near-IR dye positive) populations were 
determined by FACSCalibur flow cytometer (BD, Germany) and analyzed by 
FlowJo software (TreeStar, USA).  
 
Statistical analysis 
 
Data from all experiments were expressed as mean ± SD. The analysis was 
performed by unpaired T-test by Prism. P-value < 0.05 was considered 
statistically significant. 
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